Crossmark

Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation

Crossref DOI link: https://doi.org/10.1186/s12885-019-5268-2

Published Online: 2019-01-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tanaka, Kazuhiro http://orcid.org/0000-0002-5138-8952
Kawano, Masanori

Iwasaki, Tatsuya

Itonaga, Ichiro

Tsumura, Hiroshi
Funding

Funding for this research was provided by:

National Cancer Center Research and Development Fund (29-A-3)

Japan Agency for Medical Research and Development (JP17ck0106336)
License Information

Text and Data Mining valid from 2019-01-11

Version of Record valid from 2019-01-11
More Information

Article History

Received: 3 October 2018

Accepted: 2 January 2019

First Online: 11 January 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below